Safety and Efficacy Study in Patients With Major Depressive Disorder

Summary

The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The safety and how well the body can handle the drug will also be investigated. The study will be conducted in Russia in hospitalised patients with severe depression. GSK163090 will be compared with placebo, which looks like the study drug but does not contain any active substance. Subjects will be given either the study drug or the matching placebo.

Timeline

Start

2009-04-23

Primary completion

2010-02-09

Completion

2010-02-09

Drugs

Indications